GlyphAgo

Seaport Therapeutics initiated a Phase 1 trial for GlyphAgo (SPT-320), an oral prodrug of agomelatine, targeting Generalized Anxiety Disorder (GAD). GlyphAgo utilizes the Glyph™ technology to enhance agomelatine’s bioavailability by promoting lymphatic absorption, bypassing first-pass liver metabolism. The study will assess safety, tolerability, and pharmacokinetics, aiming to achieve therapeutic agomelatine levels at lower doses to reduce liver exposure. This marks Seaport’s second therapeutic candidate entering clinical development.